Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy
about
Improving the clinical impact of biomaterials in cancer immunotherapy.Materials based tumor immunotherapy vaccinesStructure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery systemSynthetic Nanoparticles for Vaccines and ImmunotherapyEngineering New Approaches to Cancer VaccinesNanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation.Combinatorial Delivery of Dual and Triple TLR Agonists via Polymeric Pathogen-like Particles Synergistically Enhances Innate and Adaptive Immune Responses.Immunoliposome co-delivery of bufalin and anti-CD40 antibody adjuvant induces synergetic therapeutic efficacy against melanoma.Gold nanoparticle delivery of modified CpG stimulates macrophages and inhibits tumor growth for enhanced immunotherapyIn vivo gold nanoparticle delivery of peptide vaccine induces anti-tumor immune response in prophylactic and therapeutic tumor models.Liposome-based polymer complex as a novel adjuvant: enhancement of specific antibody production and isotype switch.Multivalent porous silicon nanoparticles enhance the immune activation potency of agonistic CD40 antibody.Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity.Construction and Immunological Evaluation of CpG-Au@HBc Virus-Like Nanoparticles as a Potential Vaccine.Engineering nano- and microparticles to tune immunityGold nanoparticle mediated cancer immunotherapyNanocarrier possibilities for functional targeting of bioactive peptides and proteins: state-of-the-art.The use of agonistic anti-CD40 therapy in treatments for cancer.Microenvironment of tumor-draining lymph nodes: opportunities for liposome-based targeted therapy.Harnessing biomaterials to engineer the lymph node microenvironment for immunity or tolerance.Engineered Materials for Cancer Immunotherapy.Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook.Combinatorial drug delivery approaches for immunomodulation.Biomaterials for enhancing anti-cancer immunity.Emerging nanotechnologies for cancer immunotherapyImaging the pharmacology of nanomaterials by intravital microscopy: Toward understanding their biological behavior.Delivery of therapeutics with nanoparticles: what's new in cancer immunotherapy?Low-dose controlled release of mTOR inhibitors maintains T cell plasticity and promotes central memory T cells.Delivering safer immunotherapies for cancer.Controlling melanoma at local and systemic levels: is a combination of ablative therapy and immunotherapy the way forward?Functional nanocarrier for drug and gene delivery via local administration in mucosal tissues.Immunoengineering with biomaterials for enhanced cancer immunotherapy.Synthetic immune niches for cancer immunotherapy.Control of autoimmune inflammation using liposomes to deliver positive allosteric modulators of metabotropic glutamate receptors.Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells.Self-Assembled Nano-Immunostimulant for Synergistic Immune Activation.Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment.MRI monitoring of nanocarrier accumulation and release using Gadolinium-SPIO co-labelled thermosensitive liposomes.A Dual Immunotherapy Nanoparticle Improves T-Cell Activation and Cancer Immunotherapy.Thermo-Sensitive Liposome co-Loaded of Vincristine and Doxorubicin Based on Their Similar Physicochemical Properties had Synergism on Tumor Treatment.
P2860
Q26766267-D9684DED-D7F5-482B-837D-A03BD24A0A2DQ26824135-D1F4CDF1-6A79-4602-9A45-55CCF6B2C6D8Q27004381-490FC81E-9901-41B5-9C7E-A89FD4003CCAQ28085375-5D34C614-7B6A-44CC-99EF-4AED1424BC6CQ28085563-EB7E8773-0C1F-462F-A85F-FC1EBF9AF87DQ30844270-21C4CD67-832D-4DED-8DE7-FE2968A7C8C2Q33746872-152CEEB7-14EB-4812-8178-428A3ABA0A4CQ34661963-57647A47-1C80-4277-B6DC-9688E7312C93Q34730651-145FD299-AC1C-475C-B04B-D988FFEDBDF8Q35217609-CBD7ABA7-16D6-432E-89EF-F550F995BC5AQ35750626-00385A73-E096-454D-B66D-3D84D8330595Q36452648-E2EA9471-915A-4F84-8773-7D13D89FDA76Q36675055-C87CC614-D135-4DE6-95F3-C7D75077B125Q37110039-21A363C2-8940-42C1-925E-F22CE9033C26Q37205125-B3346356-C51E-407B-896C-306C4F7FD0BAQ37666077-FF11EAE5-47B6-400B-A210-F856DA15FD9BQ37948968-58B76EDF-D185-4FAA-B725-38834C8F0221Q38026924-A687C8CF-DD6D-478A-8899-E6C465884D60Q38266149-C902670E-3DA8-4548-A51E-8958D6C4338DQ38297557-6337AE4F-3AAE-4E03-9DE4-E34445327492Q38660577-CF5C8B8A-FFD8-4C12-A19F-FDF2A7A929EEQ38677432-0A9BAD2A-7B67-448B-95DC-5968EEBC287FQ38680602-91DAA574-CBCA-4342-A1FF-1F2380004026Q38741829-2AC582DB-0479-4236-9C9F-55FA8DF3A1E6Q38837036-910FBCD2-6700-4851-8730-27DDDEB7CF7FQ38856246-B52CFF1F-B4D5-4EE4-AFDB-220B611A4B64Q38912004-2F77D74D-44CD-4C2B-B439-8365CD2821F4Q38930638-AAB7E307-4416-4CBD-B528-049C02590CA5Q39330984-70A3F84F-CC08-4EF0-9A7E-03AB8D321B2AQ39738697-DBAA195A-0136-43FA-A4CA-94521826E8B1Q47316408-48744F67-BF58-48FB-A59F-975B76C90A9EQ47732542-39E2222E-22A6-4A8D-A8E0-B9D89F09AD88Q47739711-C261CEC7-6B44-4413-9544-ADBDFEAB71EDQ47846395-50D2F633-C971-452A-AACC-0F58CFE0D405Q48243270-C3F51F20-FC2F-48C7-B8E9-B9B7861466B2Q48761437-8DF9E011-B7B8-46A2-9478-C63C691F1409Q49391681-98D6E0AA-4BE6-4D80-9412-C0A78645AC09Q50240636-EB139226-AF2E-49D3-862C-E7B285D18B16Q52565193-65AB02F9-A0F0-45A1-B061-C94362CDECABQ53123294-92ADA28E-E186-4F45-A65A-8C99FDCE4F65
P2860
Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Induction of potent anti-tumor ...... ed combinatorial immunotherapy
@ast
Induction of potent anti-tumor ...... ed combinatorial immunotherapy
@en
type
label
Induction of potent anti-tumor ...... ed combinatorial immunotherapy
@ast
Induction of potent anti-tumor ...... ed combinatorial immunotherapy
@en
prefLabel
Induction of potent anti-tumor ...... ed combinatorial immunotherapy
@ast
Induction of potent anti-tumor ...... ed combinatorial immunotherapy
@en
P2093
P2860
P1433
P1476
Induction of potent anti-tumor ...... ed combinatorial immunotherapy
@en
P2093
Brandon Kwong
Darrell J Irvine
Haipeng Liu
P2860
P304
P356
10.1016/J.BIOMATERIALS.2011.03.067
P577
2011-04-22T00:00:00Z